SEC Form 3 filed by new insider Gillings John T

$SSKN
Medical/Dental Instruments
Health Care
Get the next $SSKN alert in real time by email
SEC FORM 3 SEC Form 3
FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person*
Gillings John T

(Last) (First) (Middle)
C/O STRATA SKIN SCIENCES, INC.
5 WALNUT GROVE DRIVE, SUITE 140

(Street)
HORSHAM PA 19044

(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
11/13/2024
3. Issuer Name and Ticker or Trading Symbol
STRATA Skin Sciences, Inc. [ SSKN ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Accounting Officer
5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
No securities are beneficially owned.
/s/ John T Gillings 11/14/2024
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Get the next $SSKN alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$SSKN

DatePrice TargetRatingAnalyst
More analyst ratings

$SSKN
Press Releases

Fastest customizable press release news feed in the world

See more
  • STRATA Skin Sciences Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides a Corporate Update

    HORSHAM, Pa., March 27, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. ("STRATA" or the "Company") (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces its financial results for the quarter and year ended December 31, 2024, and provides a corporate update. Fourth Quarter and Full-Year 2024 Financial Highlights Revenue in the fourth quarter of 2024 was $9.6 million, up 10% from $8.7 million in the year-ago quarter Global net recurring XTRAC® revenue in the fourth quarter was $5.5 million vs. $5.4 million in the prior year period, with international growth of 13%

    $SSKN
    Medical/Dental Instruments
    Health Care
  • STRATA Skin Sciences to Report Fourth Quarter and Year End 2024 Financial Results on March 27, 2025 and Provide Corporate Update

    HORSHAM, Pa., March 21, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. ("STRATA" or the "Company") (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces that it will report fourth quarter and year end 2024 financial results on Thursday, March 27, 2025 after the market close. STRATA management will host a conference call at 4:30 p.m. ET on Thursday, March 27, 2025 to review financial results and provide an update on corporate developments. Following management's formal remarks, there will be a question-and-answer session. To listen to the conference call, interest

    $SSKN
    Medical/Dental Instruments
    Health Care
  • STRATA Skin Sciences Highlights New Clinical Study from Japan Demonstrating Superiority of Narrow Band Excimer Laser Over Non Narrow Band UVB-Source Like Excimer Light

    HORSHAM, Pa., March 20, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. ("STRATA" or the "Company") (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces the results of a newly published study in Japan that further validates the technological advantages of high repetition rate, high dose, coherent collimated narrow band Excimer Laser technology over other sources of UVB light that are less accurate, lack the repetition rate and/or fluence capabilities of an Excimer Light for treating Vitiligo, Psoriasis, Alopecia Areata and Atopic Dermatitis. The study, titled "Exci

    $SSKN
    Medical/Dental Instruments
    Health Care

$SSKN
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$SSKN
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$SSKN
SEC Filings

See more

$SSKN
Leadership Updates

Live Leadership Updates

See more
  • Apyx Medical Corporation Appoints Matthew Hill as Chief Financial Officer

    Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical;" the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced the appointment of Matthew Hill to the position of Chief Financial Officer, effective December 4, 2023. Mr. Hill succeeds Tara Semb, whose departure was announced by the Company on November 9, 2023. "Matt joins our executive leadership team with over 30 years of financial and operational experience, more than 20 years of which has been in the healthcare industry, where he has served as the Chief Financial Officer of four publicly-traded healthcare companies," said Charlie Goodwin, President and

    $APYX
    $PDSB
    $SSKN
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
  • STRATA Skin Sciences Appoints Dr. Uri Geiger to Chairman of its Board of Directors

    HORSHAM, Pa., June 30, 2023 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today announced the appointment of Dr. Uri Geiger as the Chairman of the Board of Directors. William Humphries will step down as Chairman and continue to serve on the Board, effective July 3, 2023, as he transitions into his role as Chief Executive Officer of Alcami Corporation. "I'm honored to assume the role of Chairman at this pivotal moment in STRATA's growth," said Dr. Uri Geiger, Chairman of STRATA's Board of Directors. "I look forward to levera

    $SSKN
    Medical/Dental Instruments
    Health Care
  • STRATA Skin Sciences Appoints Patricia S. Walker, M.D., Ph.D. to its Board of Directors

    HORSHAM, Pa., Feb. 14, 2022 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, announced that effective today, Patricia S. Walker M.D., PhD. has been appointed to its Board of Directors. Dr. Walker's vast experience includes more than 35 years as a practicing dermatologist and as a corporate leader in the medical dermatology, medical aesthetics and pharmaceutical industries, executing clinical research and strategic initiatives for a wide range of companies and educational institutions. "We are delighted to welcome Patty to STRAT

    $SSKN
    Medical/Dental Instruments
    Health Care

$SSKN
Financials

Live finance-specific insights

See more
  • STRATA Skin Sciences to Report Fourth Quarter and Year End 2024 Financial Results on March 27, 2025 and Provide Corporate Update

    HORSHAM, Pa., March 21, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. ("STRATA" or the "Company") (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces that it will report fourth quarter and year end 2024 financial results on Thursday, March 27, 2025 after the market close. STRATA management will host a conference call at 4:30 p.m. ET on Thursday, March 27, 2025 to review financial results and provide an update on corporate developments. Following management's formal remarks, there will be a question-and-answer session. To listen to the conference call, interest

    $SSKN
    Medical/Dental Instruments
    Health Care
  • STRATA Skin Sciences to Report Third Quarter 2024 Financial Results on November 13, 2024 and Provide Corporate Update

    HORSHAM, Pa., Nov. 06, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. ("STRATA" or the "Company") (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces that it will report third quarter 2024 financial results on Wednesday, November 13, 2024 after the market close. STRATA management will host a conference call at 4:30 p.m. ET on Wednesday, November 13, 2024 to review financial results and provide an update on corporate developments. Following management's formal remarks, there will be a question-and-answer session. To listen to the conference call, interested part

    $SSKN
    Medical/Dental Instruments
    Health Care
  • STRATA Skin Sciences to Report Second Quarter 2024 Financial Results on August 14, 2024 and Provide Corporate Update

    HORSHAM, Pa., Aug. 07, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. ("STRATA" or the "Company") (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces that it will report second quarter 2024 financial results on Wednesday, August 14, 2024 after the market close. STRATA management will host a conference call at 4:30 p.m. ET on Wednesday, August 14, 2024 to review financial results and provide an update on corporate developments. Following management's formal remarks, there will be a question-and-answer session. To listen to the conference call, interested parties

    $SSKN
    Medical/Dental Instruments
    Health Care

$SSKN
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more